{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:52:37Z","timestamp":1790074357662,"version":"4.0.1"},"reference-count":115,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T00:00:00Z","timestamp":1552694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016R1A6A3A11933772"],"award-info":[{"award-number":["2016R1A6A3A11933772"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chonnam National University Hospital Biomedical Research Institute Grant","award":["CRI 16037-21"],"award-info":[{"award-number":["CRI 16037-21"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fibrosis is characterized by excessive deposition of the extracellular matrix and develops because of fibroblast differentiation during the process of inflammation. Various cytokines stimulate resident fibroblasts, which differentiate into myofibroblasts. Myofibroblasts actively synthesize an excessive amount of extracellular matrix, which indicates pathologic fibrosis. Although initial fibrosis is a physiologic response, the accumulated fibrous material causes failure of normal organ function. Cardiac fibrosis interferes with proper diastole, whereas pulmonary fibrosis results in chronic hypoxia; liver cirrhosis induces portal hypertension, and overgrowth of fibroblasts in the conjunctiva is a major cause of glaucoma surgical failure. Recently, several reports have clearly demonstrated the functional relevance of certain types of histone deacetylases (HDACs) in various kinds of fibrosis and the successful alleviation of the condition in animal models using HDAC inhibitors. In this review, we discuss the therapeutic potential of HDAC inhibitors in fibrosis-associated human diseases using results obtained from animal models.<\/jats:p>","DOI":"10.3390\/ijms20061329","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T12:18:53Z","timestamp":1552911533000},"page":"1329","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases"],"prefix":"10.3390","volume":"20","author":[{"given":"Somy","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaeun","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Chonnam National University Hospital, Gwangju 61469, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-8503","authenticated-orcid":false,"given":"Gwang Hyeon","family":"Eom","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M.C., and Ten Dijke, P. (2017). TGF-beta-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102157"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc. Nat. Acad. Sic. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/bloodadvances.2017010777","article-title":"Circulating fibrocytes as biomarkers of impaired lung function in adults with sickle cell disease","volume":"1","author":"Mehrad","year":"2017","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-beta: The master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in Tissue Repair, Regeneration, and Fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40139-015-0093-z","article-title":"TNFalpha in liver fibrosis","volume":"3","author":"Yang","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mam.2017.11.008","article-title":"PDGF in organ fibrosis","volume":"62","author":"Klinkhammer","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1523-1755.2000.00997.x","article-title":"Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation","volume":"57","author":"Strutz","year":"2000","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-018-0070-0","article-title":"CTGF in kidney fibrosis and glomerulonephritis","volume":"38","author":"Toda","year":"2018","journal-title":"Inflamm. Regen."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.addr.2017.07.010","article-title":"Drug targeting to myofibroblasts: Implications for fibrosis and cancer","volume":"121","author":"Yazdani","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-beta Mediated SMAD Signaling for the Prevention of Fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lawrence, J., and Nho, R. (2018). The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030778"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pharmthera.2014.02.012","article-title":"Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases","volume":"143","author":"Eom","year":"2014","journal-title":"Pharm. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5483\/BMBRep.2015.48.3.242","article-title":"Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy","volume":"48","author":"Eom","year":"2015","journal-title":"BMB Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrm.2016.159","article-title":"Histone chaperone networks shaping chromatin function","volume":"18","author":"Hammond","year":"2017","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8797206","DOI":"10.1155\/2016\/8797206","article-title":"HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases","volume":"2016","author":"Hull","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2006-03-014126","article-title":"Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: Role of microtubules","volume":"108","author":"Carta","year":"2006","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/03008207.2016.1211113","article-title":"Histone deacetylase inhibitor vorinostat (SAHA, MK0683) perturb miR-9-MCPIP1 axis to block IL-1beta-induced IL-6 expression in human OA chondrocytes","volume":"58","author":"Makki","year":"2017","journal-title":"Connect. Tissue Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1074\/jbc.M113.517599","article-title":"Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo","volume":"289","author":"Glauben","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1074\/jbc.M109.071274","article-title":"Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation","volume":"285","author":"Zhu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30358","DOI":"10.1074\/jbc.M401359200","article-title":"Requirement of histone deacetylase activity for signaling by STAT1","volume":"279","author":"Klampfer","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/annrheumdis-2015-209064","article-title":"Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes","volume":"76","author":"Angiolilli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","first-page":"L864","article-title":"Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition","volume":"297","author":"Guo","year":"2009","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.bbamcr.2007.05.016","article-title":"Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation","volume":"1773","author":"Glenisson","year":"2007","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Saito, S., Zhuang, Y., Shan, B., Danchuk, S., Luo, F., Korfei, M., Guenther, A., and Lasky, J.A. (2017). Tubastatin ameliorates pulmonary fibrosis by targeting the TGFbeta-PI3K-Akt pathway. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186615"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1095\/biolreprod.115.138115","article-title":"Epigenetic Modulation of Collagen 1A1: Therapeutic Implications in Fibrosis and Endometriosis","volume":"94","author":"Zheng","year":"2016","journal-title":"Biol. Reprod."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jjco\/hyw096","article-title":"HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy","volume":"46","author":"Zhao","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.7150\/jca.26780","article-title":"Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients","volume":"9","author":"Zhou","year":"2018","journal-title":"J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/ATVBAHA.110.221952","article-title":"Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition","volume":"31","author":"Findeisen","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2015.04.172","article-title":"HDAC inhibition: A novel therapeutic target for attenuating myocardial ischemia and reperfusion injury by reversing cardiac remodeling","volume":"190","author":"Wang","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-017-0089-1","article-title":"The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer\u2019s disease","volume":"6","author":"Yang","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"ref_36","first-page":"179","article-title":"Idiopathic Pulmonary Fibrosis: Treatment and Prognosis","volume":"9","author":"Fujimoto","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1111\/bph.12590","article-title":"A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells","volume":"171","author":"Park","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mannaerts, I., Eysackers, N., Onyema, O.O., Van Beneden, K., Valente, S., Mai, A., Odenthal, M., and van Grunsven, L.A. (2013). Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055786"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0960327114531992","article-title":"Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation","volume":"34","author":"Aher","year":"2015","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.105.559724","article-title":"Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding","volume":"113","author":"Kee","year":"2006","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/cvr\/cvn215","article-title":"Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure","volume":"80","author":"Gallo","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1161\/CIRCULATIONAHA.106.625467","article-title":"Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy","volume":"113","author":"Kong","year":"2006","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1253\/circj.CJ-09-0580","article-title":"Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats","volume":"74","author":"Cho","year":"2010","journal-title":"Circ. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.yjmcc.2008.08.015","article-title":"Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin","volume":"45","author":"Liu","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.116.234591","article-title":"Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation","volume":"358","author":"Seki","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1183\/09031936.00095113","article-title":"Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice","volume":"43","author":"Sanders","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1128\/MCB.01776-08","article-title":"Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis","volume":"29","author":"Coward","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wu, W.P., Tsai, Y.G., Lin, T.Y., Wu, M.J., and Lin, C.Y. (2017). The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3(+)IL-17(+) T cells. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0630-6"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14495","DOI":"10.1038\/s41598-017-15162-6","article-title":"Trichostatin A ameliorates renal tubulointerstitial fibrosis through modulation of the JNK-dependent Notch-2 signaling pathway","volume":"7","author":"Tung","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_50","first-page":"F133","article-title":"Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury","volume":"298","author":"Marumo","year":"2010","journal-title":"Am. J. Phys. Renal. Phys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11546","DOI":"10.1038\/s41598-018-30008-5","article-title":"Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease","volume":"8","author":"Choi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_52","first-page":"F729","article-title":"Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury","volume":"297","author":"Noh","year":"2009","journal-title":"Am. J. Phys. Renal. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.ALC.0000106301.39746.EB","article-title":"Liver disease in heavy drinkers with and without alcohol withdrawal syndrome","volume":"28","author":"Barrio","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJMc091513","article-title":"Alcoholic hepatitis","volume":"361","author":"Mohammed","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ijc.30782","article-title":"Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers","volume":"141","author":"Chu","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yjmcc.2015.12.024","article-title":"The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction","volume":"91","author":"Lindsey","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.hrthm.2006.12.040","article-title":"Atrial fibrosis and the mechanisms of atrial fibrillation","volume":"4","author":"Everett","year":"2007","journal-title":"Heart Rhythm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jacc.2007.09.064","article-title":"Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation","volume":"51","author":"Burstein","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"ref_62","first-page":"3250","article-title":"Atrial fibrillation in heart failure: What should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s12276-018-0121-2","article-title":"PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart","volume":"50","author":"Yoon","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/CIRCULATIONAHA.110.003665","article-title":"Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart","volume":"123","author":"Eom","year":"2011","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1128\/MCB.24.19.8467-8476.2004","article-title":"Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development","volume":"24","author":"Chang","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1101\/gad.1563807","article-title":"Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility","volume":"21","author":"Montgomery","year":"2007","journal-title":"Genes Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/01.CIR.0000020689.12472.E0","article-title":"Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats","volume":"106","author":"Kuwahara","year":"2002","journal-title":"Circulation"},{"key":"ref_68","first-page":"H824","article-title":"Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse","volume":"301","author":"Reed","year":"2011","journal-title":"Am. J. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry","volume":"53","author":"Hernandez","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2009.06.067","article-title":"Treatment of heart failure with normal ejection fraction: An inconvenient truth!","volume":"55","author":"Paulus","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Meraviglia, V., Bocchi, L., Sacchetto, R., Florio, M.C., Motta, B.M., Corti, C., Weichenberger, C.X., Savi, M., D\u2019Elia, Y., and Rosato-Siri, M.D. (2018). HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca(2+)-ATPase Activity in Cardiac Myocytes. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020419"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.114.303429","article-title":"Regulation of acetylation of histone deacetylase 2 by p300\/CBP-associated factor\/histone deacetylase 5 in the development of cardiac hypertrophy","volume":"114","author":"Eom","year":"2014","journal-title":"Circ. Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yoon, S., Kim, M., Min, H.-K., Lee, Y.-U., Kwon, D.-H., Lee, M., Lee, S., Kook, T., Joung, H., and Nam, K.-I. (2018). Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2. Cardiovasc. Res.","DOI":"10.1093\/cvr\/cvy317"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","article-title":"Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload","volume":"131","author":"Schiattarella","year":"2015","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/mi.2008.85","article-title":"Pulmonary fibrosis: Pathogenesis, etiology and regulation","volume":"2","author":"Wilson","year":"2009","journal-title":"Mucosal. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2005080799","article-title":"A pathogenetic role for mast cells in experimental crescentic glomerulonephritis","volume":"17","author":"Timoshanko","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/invivo.11019","article-title":"Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies","volume":"31","author":"Nogueira","year":"2017","journal-title":"In Vivo"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00011-007-6145-z","article-title":"Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy","volume":"56","author":"Suzuki","year":"2007","journal-title":"Inflamm. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1073\/pnas.90.5.1814","article-title":"Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy","volume":"90","author":"Yamamoto","year":"1993","journal-title":"Proc. N. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1681\/ASN.2016060603","article-title":"Beyond EMT: Epithelial STAT3 as a Central Regulator of Fibrogenesis","volume":"27","author":"Duffield","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ki.2009.86","article-title":"Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy","volume":"75","author":"Chevalier","year":"2009","journal-title":"Kidney Int."},{"key":"ref_89","first-page":"F996","article-title":"Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy","volume":"297","author":"Pang","year":"2009","journal-title":"Am. J. Phys. Renal. Phys."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease","volume":"350","author":"Wilson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1148\/radiol.2016151650","article-title":"Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations","volume":"280","author":"Kim","year":"2016","journal-title":"Radiology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.ejhg.5201162","article-title":"Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2)","volume":"12","author":"Boucher","year":"2004","journal-title":"Eur. J. Hum. Gen."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, Encoding the Glucosidase IIalpha Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am. J. Hum. Gen."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"17897","DOI":"10.1074\/jbc.M117.803775","article-title":"Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca(2+) in knock-out mouse models of polycystic kidney disease","volume":"292","author":"Yanda","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"Proc. N. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Gen."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1573406412666160608113235","article-title":"Cystic Fibrosis Revisited\u2014A Review Study","volume":"13","author":"Klimova","year":"2017","journal-title":"Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12931-017-0705-8","article-title":"Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses","volume":"19","author":"Bodas","year":"2018","journal-title":"Respir. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nature15729","article-title":"F508 CFTR interactome remodelling promotes rescue of cystic fibrosis","volume":"528","author":"Pankow","year":"2015","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nchembio.275","article-title":"Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis","volume":"6","author":"Hutt","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcp.1040980210","article-title":"Growth kinetics and collagen synthesis of normal skin, normal scar and keloid fibroblasts in vitro","volume":"98","author":"Diegelmann","year":"1979","journal-title":"J. Cell. Physiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00055735-200104000-00011","article-title":"Modulation of wound healing after glaucoma surgery","volume":"12","author":"Khaw","year":"2001","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5005\/jp-journals-10008-1164","article-title":"Intraocular Pressure Control after Trabeculectomy, Phacotrabeculectomy and Phacoemulsification in a Hispanic Population","volume":"8","author":"Jung","year":"2014","journal-title":"J. Curr. Glaucoma. Pract."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ophtha.2008.08.009","article-title":"Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery","volume":"116","author":"Hall","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","article-title":"Glaucoma treatment trends: A review","volume":"52","author":"Conlon","year":"2017","journal-title":"Can. J. Ophthalmol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1167\/iovs.18-23826","article-title":"Trichostatin A Ameliorates Conjunctival Fibrosis in a Rat Trabeculectomy Model","volume":"59","author":"Sung","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/jid.2011.432","article-title":"Histone deacetylase 2 is upregulated in normal and keloid scars","volume":"132","author":"Badshah","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/jid.2010.162","article-title":"Epigenetically altered wound healing in keloid fibroblasts","volume":"130","author":"Russell","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"61e","DOI":"10.1097\/PRS.0b013e318290f698","article-title":"Histone deacetylase inhibitor reduces hypertrophic scarring in a rabbit ear model","volume":"132","author":"Diao","year":"2013","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","article-title":"Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL","volume":"21","author":"Stubbs","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1096\/fj.14-257931","article-title":"HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis","volume":"29","author":"Zimberlin","year":"2015","journal-title":"FASEB J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10492","DOI":"10.1038\/ncomms10492","article-title":"MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification","volume":"7","author":"Kwon","year":"2016","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:38:20Z","timestamp":1760186300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/6\/1329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,16]]},"references-count":115,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["ijms20061329"],"URL":"https:\/\/doi.org\/10.3390\/ijms20061329","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,16]]}}}